NCT01731106

Brief Summary

Brief Summary Cerebral Autoregulation is a well known physiological response to blood pressure changes to maintain the cerebral perfusion. The critically ill patients are submitted to different situations that can impair the cerebral autoregulation as sepsis, sedation drugs and mechanical ventilation. The delirium on ICU has been described as a bad prognosis factor, increasing the mortality and length of stay. The physiopathology of delirium has been related to cerebral perfusion. The delirium has been related to long term cognitive impairment. Material and Methods: This is a physiological prospective study that will be done in a 14 bed medical-surgical ICU. The investigators will enroll 100 ventilated patients, septic and non-septic. The investigators will measure cerebral autoregulation every 48-72 hours from admission on ICU. Neurological biomarkers (Neurological Specific Enolase, S100 beta and Vascular Endothelial Growing Factor) will be done at inclusion, 72 hours and 7 days. Clinical data, delirium presence, analytic data and ventilatory parameters will be registered every day. At hospital discharge, a psychologist will do a cognitive evaluation using specific tests. The cognitive evaluation will be repeated at 3, 6 and 12 months. Anticipate results: Some items like mechanical ventilation, sepsis and sedation can impair cerebral autoregulation. The impairment of cerebral autoregulation is related to delirium in ICU and long cognitive impairment.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2012

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

November 13, 2012

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 21, 2012

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

June 27, 2018

Status Verified

June 1, 2018

Enrollment Period

5.5 years

First QC Date

November 13, 2012

Last Update Submit

June 26, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • To describe the incidence of impairment of cerebral autoregulation in critically ill patients.

    7 days

Secondary Outcomes (2)

  • To describe the incidence of delirium in critically ill patients with or without impairment of cerebral autoregulation

    30 days

  • To describe the long term cognitive impariment in critically ill patients.

    3, 6 and 12 months

Other Outcomes (1)

  • To describe the survival of patients who have impairment of cerebral autoregulation

    3 months

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients admited on the ICU that need mechanical ventialtion

You may qualify if:

  • Patients older than 18 years old of age.
  • Patients under mechanical ventilation and/or sedation drugs and/or severe sepsis as defined on international criteria.
  • Patients with arterial line.

You may not qualify if:

  • Acute neurological pathology.
  • Absence of arterial line.
  • Severe haemodynamic instability defined as Mean Arterial Pressure (MAP) lower than 70 mmHg even with pressors.
  • Absence of temporal bone window for doing TCD.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Carles Subira Cuyas

Manresa, Barcelona, 08243, Spain

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood sample for biomarkers at admision, 72 hours and 7 days.

MeSH Terms

Conditions

Critical IllnessSystemic Inflammatory Response Syndrome

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsInflammationShock

Study Officials

  • Rafael Fernandez, Ph, MD

    Head of Department

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician Doctor

Study Record Dates

First Submitted

November 13, 2012

First Posted

November 21, 2012

Study Start

June 1, 2012

Primary Completion

December 1, 2017

Study Completion

March 1, 2018

Last Updated

June 27, 2018

Record last verified: 2018-06

Locations